Salvatore Intagliata

Author

Istituti di Ricovero e Cura a Carattere Scientifico

Also Known As

S. Intagliata, Salvatore Intagliata

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico Università Campus Bio-Medico Azienda Ospedaliera Universitaria Pisana University of Messina Azienda Ospedaliera Treviglio

About

Salvatore Intagliata is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	821
2	Immunology	2	2	186
3	Health Sciences	1	1	165
4	Public Health	1	1	621
5	Epidemiology	1	1	621

Salvatore Intagliata

Publications

997

Citations

H-Index

Page 1

	Year	Citations
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Marina Chiara Garassino, Jennifer G. Whisenant, Li‐Ching Huang, The Lancet Oncology Virus EpidemiologyMedicineCovid-19 PandemicClinical EpidemiologyInternational Health	2020	621
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study Alessandro Russo, Marco Russano, Tindara Franchina, Advances in Therapy MedicineImmunologyHematologyPathologyImmune Checkpoint Inhibitor	2020	165
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases Daniele Santini, Sandro Barni, Salvatore Intagliata, Scientific Reports	2015	136
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases Marta Laganà, Cristina Gurizzan, Elisa Roca, Frontiers in Oncology	2020	26
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation Marco Russano, Alessio Cortellini, Raffaele Giusti, Cancer Immunology Immunotherapy Cancer ImmunosurveillanceAutoimmune DiseaseMedicineImmunologyPd-1/pd-l1 Checkpoint Inhibitors	2021	21
Recurrent Scrotal Hemangiomas During Treatment With Sunitinib Giuseppe Tonini, Salvatore Intagliata, Barbara Cagli, Journal of Clinical Oncology HistopathologyVascular MalformationPathologyRecurrent Scrotal HemangiomasScleroderma	2010	14
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab Francesco Pantano, Marco Russano, Alfredo Berruti, Expert Opinion on Biological Therapy	2020	14

Page 1